Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Impax Laboratories's peak revenue was $879.5M in 2010. The peak quarterly revenue was $323.3M in 2010(q1).
Impax Laboratories's revenue increased from $273.8m in 2007 to $775.8M currently. That's a 183.39% change in annual revenue.
| Fiscal year / year | Impax Laboratories revenue |
|---|---|
| 2009 | $358.4M |
| 2010 | $879.5M |
| 2011 | $512.9M |
| 2012 | $581.7M |
| 2013 | $511.5M |
| 2014 | $596.0M |
| 2015 | $860.5M |
| 2016 | $824.4M |
| 2017 | $775.8M |
Rate Impax Laboratories' financial transparency
Impax Laboratories saw the greatest revenue growth in 2010, when revenue increased by 145.39%.
Impax Laboratories had the lowest revenue growth in 2011, when revenue changed by -41.68%.
| Year | Impax Laboratories growth |
|---|---|
| 2009 | 71%↑ |
| 2010 | 145%↑ |
| 2011 | -42%↓ |
| 2012 | 13%↑ |
| 2013 | -12%↓ |
| 2014 | 17%↑ |
| 2015 | 44%↑ |
| 2016 | -4%↓ |
| 2017 | -6%↓ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | $58.9M | $58.4M | $64.9M | $176.1M |
| 2010 | $323.3M | $153.1M | $304.0M | $99.1M |
| 2011 | $108.7M | $125.9M | $119.8M | $158.6M |
| 2012 | $128.6M | $166.5M | $145.6M | $141.1M |
| 2013 | $148.5M | $129.6M | $132.6M | $100.7M |
| 2014 | $118.7M | $188.1M | $158.0M | $131.2M |
| 2015 | $143.1M | $214.2M | $221.1M | $282.1M |
| 2016 | $225.5M | $172.6M | $227.9M | $198.4M |
| 2017 | $184.4M | $202.1M | $206.4M | $182.9M |
| 2018 | $142.4M | - | - | - |
Do you work at Impax Laboratories?
Is Impax Laboratories transparent about its revenue structure?
| CEO | Larry Hsu |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 1,257 |
| Date Founded | 1993 |
| Headquarters | Hayward, California |
| Number of Locations | 1 |
| Revenue | $775.8M |
| Net Income | -$469,287,000 |
| Gross Proft | $240.7M (2017) |
| PE Ratio | -2.83 |
| Tax Rate | -0.0% |
| Market Capitalization | $1.3B |
| Total Assets | $1,351,300,000 |
| Ticker | IPXL |
Impax Laboratories's top competitor, Bristol-Myers Squibb, earned an annual revenue of $48.3B.
Impax Laboratories's smallest competitor is Ani Pharmaceuticals with revenue of $614.4M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Akorn | $62,397 | $682.4M | 2,227 | - |
| Lannett | $67,940 | $340.6M | 1,020 | 18 |
| Actavis Laboratories FL, Inc. | $68,450 | $162.9M | 900 | - |
| Bristol-Myers Squibb | $101,824 | $48.3B | 30,000 | 1,464 |
| AGC Biologics | $66,596 | $9.8M | 2,151 | - |
| Coldstream Labs | $65,658 | $3.5M | 50 | - |
| Pliva | $59,565 | $1.2B | 1,700 | - |
| Nesher Pharmaceuticals | $73,701 | $315.3M | 124 | - |
| Baxter International | $54,368 | $10.6B | 48,000 | 163 |
| Catalent Pharma Solutions | $61,108 | $4.4B | 14,000 | 239 |
Zippia gives an in-depth look into the details of Impax Laboratories, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Impax Laboratories. The employee data is based on information from people who have self-reported their past or current employments at Impax Laboratories. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Impax Laboratories. The data presented on this page does not represent the view of Impax Laboratories and its employees or that of Zippia.
Impax Laboratories may also be known as or be related to Impax Laboratories, Impax Laboratories Inc, Impax Laboratories Inc. and Impax Laboratories, Inc.